Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

October 28, 2024 06:30 ET | Source: Ocugen

Ocugen Clinical Showcase Highlighting Progress in Retinal Gene Therapy Clinical Trials in New York City on Tuesday, November 12, 2024

Progress on OCU400 Phase 3 liMeliGhT clinical trial for retinitis pigmentosa (RP) and new data from Phase 1/2Preliminary safety and efficacy update on OCU410 Phase 1/2 ArMaDa clinical trial for...
October 22, 2024 07:02 ET | Source: Ocugen

Data and Safety Monitoring Board Approves Initiation of Phase 2 of OCU410ST GARDian Clinical Trial for Stargardt Disease

Determined the high dose of OCU410ST to be the maximum tolerated doseNo serious adverse events have been reportedApproved proceeding to Phase 2 using high and medium doses of OCU410ST MALVERN, Pa.,...
October 17, 2024 07:30 ET | Source: Ocugen

Ocugen to Host Conference Call on Friday, November 8 at 8:30 A.M. ET to Discuss Business Updates and Third Quarter 2024 Financial Results

MALVERN, Pa., Oct. 17, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and...
October 10, 2024 07:00 ET | Source: Ocugen

Ocugen to Participate in 2024 Maxim Healthcare Virtual Summit

MALVERN, Pa., Oct. 10, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and...
October 09, 2024 06:30 ET | Source: Ocugen

Ocugen, Inc. Announces Removal of Clinical Hold on Investigational New Drug Application for OCU200 Phase 1 Clinical Trial

MALVERN, Pa., Oct. 09, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene...
October 02, 2024 06:30 ET | Source: Ocugen

Ocugen to Present at the 2024 Cell & Gene Meeting on the Mesa

MALVERN, Pa., Oct. 02, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and...
September 24, 2024 07:30 ET | Source: Ocugen

Ocugen to Participate in a Fireside Chat at Chardan’s 8th Annual Genetic Medicines Conference

MALVERN, Pa., Sept. 24, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and...
September 09, 2024 06:30 ET | Source: Ocugen

Ocugen Chairman, CEO & Co-founder, Dr. Shankar Musunuri, to Speak During U.S.-India Initiative on Critical and Emerging Technology Workshop

MALVERN, Pa., Sept. 09, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene...
September 05, 2024 07:00 ET | Source: Ocugen

Ocugen CSO to Participate in 5th Annual Gene Therapy for Ophthalmic Disorders Summit

MALVERN, Pa., Sept. 05, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and...
September 03, 2024 07:30 ET | Source: Ocugen

Ocugen to Participate in a Fireside Chat at the H.C. Wainwright 26th Annual Global Investment Conference

MALVERN, Pa., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and...

keyboard_arrow_left Previous Page

Next Page keyboard_arrow_right